Cannabis Lucy Scientific Discovery acquires High Times IP, expects $10M of revenue growth in 2024 Lucy also expects to add $5 million of EBITDA to its financial results next year from the deal Rowan DunneSeptember 8, 2023
News Clearmind to collaborate with Johns Hopkins University to study promising psychedelic treatment for alcohol use disorder Johns Hopkins University School of Medicine is the second U.S. clinical site to join Clearmind's trial, following Yale School of Medicine's psychiatry department Natalia Buendia CalvilloSeptember 6, 2023
Psychedelics PharmAla Biotech lists on the OTCQB middle-tier venture market The MDMA producer is now trading under the symbol PMBHF, which is intended to attract more investors in the U.S. Rowan DunneSeptember 6, 2023
Psychedelics Otsuka Pharmaceutical seals $80M all-cash deal to acquire Mindset Pharma Mindset shareholders will receive $0.75 in cash for each share, representing a premium based on various trading metrics Natalia Buendia CalvilloAugust 31, 2023
News Silo Wellness to acquire NUGL/Kaya Group in a $43.3M deal Silo Wellness will acquire all of NUGL's issued and outstanding shares in exchange for 2 million shares from its treasury Natalia Buendia CalvilloAugust 30, 2023
Psychedelics Cybin inks agreement to acquire DMT drug developer Small Pharma The companies say they will have the most substantial dataset on the DMT molecule in the industry and largest IP portfolio Rowan DunneAugust 28, 2023
News Psychedelics may help athletes’ mental health: UoT professor Poor mental health affects not only quality of life but performance, resilience and career trajectories of athletes Natalia Buendia CalvilloAugust 23, 2023
Psychedelics Filament Health gets FDA approval for psilocybin studies on cancer-related anxiety and depression The clinical trials will examine the effects of the company's botanical psilocybin drug candidate PEX010 Rowan DunneAugust 10, 2023
News American Psychedelic Practitioners Association and BrainFutures release psychedelic-assisted therapy guidelines The model combines the use of a psychedelic medication with therapy in a single session Natalia Buendia CalvilloAugust 9, 2023
Psychedelics Cybin reaches end of psilocybin analogue clinical trial for depression CYB003 is a molecule developed by the company with rapid onset and a short duration Rowan DunneAugust 3, 2023